Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

Moura, Filipe; Berg, David; Bellavia, Andrea; Dwyer, Jamie P; Mosenzon, Ofri; Scirica, Benjamin M; Wiviott, Stephen D; Bhatt, Deepak L; Raz, Itamar; Feinberg, Mark W.; Braunwald, Eugene; Morrow, David A; S. Sabatine, Marc

doi:10.25376/hra.23932914.v1

dc230492.pdf (11.16 MB)

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

journal contribution

posted on 2023-08-11, 16:37 authored by Filipe Moura, David Berg, Andrea Bellavia, Jamie P Dwyer, Ofri Mosenzon, Benjamin M Scirica, Stephen D Wiviott, Deepak L Bhatt, Itamar Raz, Mark W. Feinberg, Eugene Braunwald, David A Morrow, Marc S. Sabatine

A novel risk model for kidney disease progression was developed and applied to stratify risk in pts with T2DM.

History

Grant ID

20SFRN35120087

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients with Type 2 Diabetes

History

Grant ID

Usage metrics

Categories

Keywords

Licence

Exports